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Effect of FK 506 Chronic Administration on Bromosulphthalein Hepatic 
Excretion in Rats 
H. Farghali, M. Sakr, A. Gasbarrini, R. Venkataramanan, J. Gavaler, T.E. Starzl, and D.H. Van Thiel 
THERE are several reports dealing with the hepatic effect of FK 506,1-4 some of which are beneficial 
while others are adverse. Because the liver is a major 
target organ that is often the site of drug toxicity, studies 
directed at determining whether FK 506 affects specific 
hepatic function and/or its histologic appearance are im-
portant. Therefore, the present study was undertaken to 
examine bromosulphthalein (BSP) elimination kinetics in 
rats as a sensitive index of hepatic excretory function 
under the influence of FK 506 in the rat. 
METHODS 
Male Sprague-Dawley rats weighing between 200 to 220 g were 
used. They were divided into three groups (J, 2, and 3) of nine, 
eight, and eight rats each, respectively. 
Group 1 rats served as the controls while groups 2 and 3 were 
the recipients of 0.4 mg/kg and 0.8 mg/kg FK 506, respectively. 
FK 506 was administered as a suspension by gavage daily to each 
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Fig 1. The mean rate of bile flow (fLUmin) as a function of 
collection time intervals in control and FK 506-treated rats at two 
dose levels for 5 to 6 weeks. Bile was collected for four successive 
intervals of 20 minutes each (mean of eight to nine ± SEM). 
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Fig 2. The plasma disappearance profile of BSP after IV admin-
istration in control and FK 506-treated rats at two dose levels of 5 
to 6 weeks. Values are means of eight to nine plasma samples ± 
SEM. 
animal in groups 2 and 3 while the animals in group I were given 
0.4 mUrat of drinking water by gavage. All animals were treated 
for 5 to 6 weeks. The day after the last dose, the animals were 
anesthetized with pentobarbitone sodium (50 mg/kg intraperitone-
ally). After a median laparatomy, the bile duct was cannulated for 
bile collection using polyethylene tubing (Clay Adams PE-IO). 
The left and right femoral veins were catheterized with polyeth-
ylene tubing for administration of BSP and blood sampling, 
respectively. BSP solution in normal saline was injected as a 5 
mg/kg in the left femoral venous PE line. Bile was collected in 
preweighed Eppendorf polethylene tubes over four successive 
sampling periods of20 minutes each, ie, up to 80 minutes. The bile 
samples were weighed immediately, and kept at -10°C until being 
analyzed. Blood samples were collected from the right femoral 
vein at the midpoint of each bile collection interval with the 
exception of the first blood sample, which was obtained 5 minutes 
after the IV administration of the BSP. After each blood with-
From the Department of Surgery, University of Pittsburgh 
School of Medicine, Pittsburgh, Pennsylvania. 
Address reprint requests to H. Farghali, MD, Department of 
Surgery, University of Pittsburgh School of Medicine, Pittsburgh, 
PA. 
© 1991 by Appleton & Lange 
0041-1345/91/$3.00/+0 
2802 Transplantation Proceedings, Vol 23, No 6 (December), 1991: pp 2802-2804 
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Fig 3. (A) The mean rate of BSP excretion (p.g/min) as a function 
of collection intervals in control and FK 506-treated rats at two 
dose levels for 5 to 6 weeks. Bile was collected for four successive 
intervals of 20 minutes each. (mean of eight to nine ± SEM). (8) 
The cumulative biliary excretion of BSP as a function of time after 
IV administration of 5 mg/kg in control and FK 506-treated rats at 
two dose levels for 5 to 6 weeks. 
drawal (0.8 to I mL), an equivalent volume of physiologic saline 
was slowly administered through the left femoral IV line to 
maintain vascular volume . After the last bile sample was obtained 
additional blood was withdrawn for enzyme analysis. The con-
centration of SSP in the plasma and bile was determined spectro-
photometrically after a n appropriate dilution of the sample with an 
alkaline buffer containing p-toluene sullfonic acid (pH 10.4) at 580 
nm with a n HP spectrophotometer (nine rats). Plasma aminotrans-
ferases levels (alanine transaminase [ALT) and aspartate trans-
aminase [AST)) were determined using standard kits. 
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RESULTS 
The chronic administration of FK 506 at either dose level 
(0.4 mg/kg or 0.8 mg/kg) did not produce a significant 
change in the rate of bile flow as compared with that of the 
controls with the exception of the last sample collected 
from animals receiving the higher dose of FK 506 (0.8 
mg/kg) as shown in Fig 1 (P < .05) . The plasma disappear-
ance profile of BSP after IV administration in the three 
groups is illustrated in Fig 2. The rats receiving 0.4 mg/kg 
of FK 506 exhibited the same plasma concentrations as did 
the controls at different sampling intervals. The rats that 
were given the higher FK 506 dose had statistically greater 
plasma BSP concentrations than did the controls at both 
the first and last time points (6.4 ± 1.06 and 0.3 ± II in the 
treated group as compared with 3.7 ± 0.77 and 0.2 ± 0.07 
in controls, respectively). The rate of biliary BSP excre-
tion was plotted as the amount excreted per 20 minutes as 
a function of time . Both the control rats and the FK 506 
lower dose group had similar rates of BSP excretion (Fig 
3A). The BSP biliary excretion rate was highest during the 
first 20 minutes . The BSP biliary excretion rate for the 
animals receiving the 0.8 mg/kg of FK 506 dose was 
reduced at the first time point. The cumulative biliary 
excretion of BSP as a function of time was similar in all the 
three groups after 80 minutes, however, as shown in Fig 
3B. Nearly the entire BSP dose was excreted by 80 
minutes (range 99.5% to 110%). 
The values for serum ALT and AST in the three groups 
of rats are shown in Fig 4. Rats that received the lower 
dose of FK 506 did not differ from the controls. On the 
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Fig 4. The mean values of plasma AL T and AST in control and 
FK 506-treated rats at two dose levels for 5 to 6 weeks (mean of 
eight to nine ± SEM). 
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other hand , the rats receiving 0.8 mg/kg FK 506 exhibited 
a threefold and fourfold increase in plasma AL T and AST 
levels compared with the controls (P < .05). 
DISCUSSION 
There are few available reports that deal with the interac-
tion between FK 506 and the liver,J -5 especially those 
concerning effects after multiple dose administration . The 
present study was designed to shed light on the effect of 
subacute (5 to 6 weeks) administration of FK 506 at two 
doses on the biliary excretion of BSP. These experiments 
demonstrate that, after subacute treatment of rats for 5 to 
6 weeks with 0.4 mg/kg, BSP uptake by the liver, bile flow, 
BSP excretion rate, and total excretion are normal. This is 
true whether one considers BSP retention a t different 
blood sampling times or BSP rate or cumulative excretion 
into the bile. The BSP excretion test is a sensitive mea-
surement of liver excretory function. 6 Thus, the present 
data demonstrate that in rats at the lower dose of FK 506, 
subacute treatment does not modify hepatic excretory 
function. Plasma AST and AL T levels, which measure 
liver cell damage or necrosis/ were also not raised with 
the low dose of FK 506. However , at the higher dose level 
a significant increase in both enzyme levels occurred . This 
was accompanied by an initial increase in the plasma value 
of BSP 5 minutes after IV administration . Moreover , the 
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rate of BSP disappearance from the blood and appearance 
in the bile was slightly reduced compared with the con-
trols . However , no cholestasis occurred as evidenced by a 
normal rate of bile flow . In conclusion , within the present 
experimental limitation , subchronic administration of FK 
506 at a dose of 0.4 mg/kg did not produce a deleterious 
effect on hepatic excretory function . The higher dose 
produced a slight inhibition of hepatic excretory function 
and moderately increased the plasma aminotransferases 
levels. 
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